Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
- PMID: 17420930
- DOI: 10.1007/s00415-006-0332-7
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies
Abstract
To analyze the in vivo biological effect of anti-interferon beta (IFN-beta) neutralizing antibodies (NABs), blood concentrations of neopterin, beta2microglobulin (Beta2-MG), mRNA-dependent myxovirusresistant protein A (MxA) and dsRNA-dependent protein kinase (PKR) were measured before (predose) and 24 hours after (postdose) IFN-beta administration in 49 patients with multiple sclerosis (MS) with (n = 25) and without (n = 24) NABs. The results indicated that predose levels of MxA-mRNA and PKR-mRNA were highly variable [coefficient of variation (CV) > 100%] among patients. A lower inter-individual variability was observed for pre-dose levels of Beta2-MG and neopterin (CVs of 29% and 44%, respectively). Significantly lower pre- and post-dose blood levels of IFN induced markers, except for postdose PKR-mRNA (p = 0.09), were seen in NAB+ compared with NAB-patients and between patients with high (> 200 t(1/10)) and low ( pound 200 t(1/10)) NAB titers. A significant inverse correlation between NAB titer and pre-dose levels of the above IFN-induced markers was found. In summary, our findings confirm that NABs affect absolute concentrations of IFN-beta induced markers and suggest that such an effect occurs in a titer-dependent manner.
Similar articles
-
Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.Mult Scler. 2011 Nov;17(11):1333-40. doi: 10.1177/1352458511412654. Epub 2011 Jun 17. Mult Scler. 2011. PMID: 21685230
-
Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.J Neuroimmunol. 2006 Jul;176(1-2):125-33. doi: 10.1016/j.jneuroim.2006.03.019. Epub 2006 May 15. J Neuroimmunol. 2006. PMID: 16698090
-
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.Eur J Neurol. 2012 Oct;19(10):1311-7. doi: 10.1111/j.1468-1331.2012.03721.x. Epub 2012 May 5. Eur J Neurol. 2012. PMID: 22564111
-
Neutralizing antibodies to interferon.Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22. doi: 10.1212/01.wnl.0000277705.63813.84. Neurology. 2007. PMID: 17562846 Review.
-
Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB).Neurology. 2003 Nov 11;61(9 Suppl 5):S24-6. doi: 10.1212/01.wnl.0000092361.04511.d0. Neurology. 2003. PMID: 14610107 Review.
Cited by
-
Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.CNS Drugs. 2009;23(5):379-96. doi: 10.2165/00023210-200923050-00003. CNS Drugs. 2009. PMID: 19453200 Review.
-
Neutralizing antibodies against interferon-Beta.Ther Adv Neurol Disord. 2008 Sep;1(2):125-41. doi: 10.1177/1756285608095144. Ther Adv Neurol Disord. 2008. PMID: 21180570 Free PMC article.
-
Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.J Interferon Cytokine Res. 2013 Nov;33(11):660-71. doi: 10.1089/jir.2012.0079. Epub 2013 Jul 13. J Interferon Cytokine Res. 2013. PMID: 23848523 Free PMC article.
-
Determinants of interferon β efficacy in patients with multiple sclerosis.Nat Rev Neurol. 2011 Apr;7(4):221-8. doi: 10.1038/nrneurol.2011.22. Epub 2011 Mar 1. Nat Rev Neurol. 2011. PMID: 21364522 Review.
-
Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.BMC Neurol. 2009 Oct 13;9:54. doi: 10.1186/1471-2377-9-54. BMC Neurol. 2009. PMID: 19825153 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical